Western drugmakers headed into the BRIC countries to provide the kind of volume growth they couldn't scare up elsewhere. But it is not turning out exactly as planned. India has expanded price controls.
An FDA import ban can be costly, and India's Wockhardt says the import alert it is now under could slice $100 million out of its revenues.
Johnson & Johnson just can't seem to get its consumer health manufacturing in order.
Johnson & Johnson built its R&D rep around blockbuster development deals. Now the pharma giant's drug development arm wants the world to know that there's a comprehensive, global pipeline strategy in play that will deliver more than 10 new product applications over the next 4 years. And new drug development efforts in China and Japan are growing to rival the work it does in the U.S. and Europe.
Recruiting for vacant senior positions is a balancing act between identifying the ideal person and hiring quickly to avoid a power vacuum. Pakistan's National Institutes of Health (NIH) seems to be struggling to find this balance. Its search for an executive director is now in its fifth year.
China has often been maligned in Africa as the source of counterfeit drugs, a reputation that the government is not at all happy about. Chinese authorities this year even took the unusual step of defending their country against a report in a U.K. newspaper that it was a primary source of fake antimalarial drugs in Uganda and Tanzania.
New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.
Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese companies see the tie-ups as a way to build their own capabilities and begin to tap lucrative Western markets.
India has started the countdown on new price controls for a vastly expanded list of drugs, a move that is expected to cut deeply into the profits of drugmakers for hundreds of drugs.
GlaxoSmithKline CFO Simon Dingemans has found one of the mainstays of retail works just fine for drugs, particularly in emerging markets where GSK wants to build its foothold. You just put them on sale.